AO-176
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2691109-74-5
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Human
CD47
AO-176 shows EC50 values of 130 ng/mL (OV90), 390 ng/mL (HCC827), 649 ng/mL (SNU-1), 250 ng/mL (OV10-315), 2700 ng/mL (MDA-MB-231), 390 ng/mL (Jurkat) and 1910 ng/mL (Raji)[1].
AO-176 (10 μg/mL, 24 h) induces death of Jurkat and OV90 cells[1].
AO-176 (0.017-1000 μg/mL) binds negligibly to RBCs and does not cause agglutination of washed human RBCs[1][3].
AO-176 (10-30 μg/mL, 24 h) has no killing effect on normal cell and the activated T cells[1].
AO-176 (0.001-100 μg/mL, 90 min) directly inhibits the binding of SIRPα to CD47 on Jurkat cells with an IC50 of 0.78 to 0.87 μg/mL[1].
AO-176 (0.01-10 μg/mL, 2 h) promotes the phagocytosis of both Jurkat, Raji, OV90, Detroit 562, and FaDu cells in a concentration-dependent manner[1][2][4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
AO-176 (1-25 mg/kg, i.v., weekly for 4 weeks) significantly suppresses the tumor growth in Raji lymphoma xenograft mice models[1].
AO-176 (10-25 mg/kg, i.p., weekly or 5 times/weeks for 5-6 weeks) significantly suppresses the tumor growth in MDA-MB-23, SNU-1 and OV90 xenograft mice models[1].
AO-176 (3-25 mg/kg) exerts anti-tumor activity in RPMI-8226 and NCI-H929 xenografted mice models[3][4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Raji lymphoma xenograft models (female, NSG, 5 weeks)[1][4]
-
Dosage:1, 10, and 25 mg/kg
-
Administration:Intravenous injection, weekly for 4 weeks
-
Result:Inhibited tumor growth by 25% at 1 mg/kg, 73% at 10 mg/kg and 82% at 25 mg/kg.
-
Animal Model:MDA-MB-231 TNBC xenograft models (female, NSG, 5 weeks)[1]
-
Dosage:15 mg/kg
-
Administration:Intraperitoneal injection, 5 times/weeks for 5 weeks
-
Result:Showed tumor growth inhibition of 83%.
-
Animal Model:SNU-1 gastric carcinoma xenograft models (female, NSG, 5 weeks)[1]
-
Dosage:25 mg/kg
-
Administration:Intraperitoneal injection, 5 times/week for 6 weeks
-
Result:Showed tumor growth inhibition of 64%.
-
Animal Model:OV90 ovarian carcinoma xenograft models (female, NSG, 5 weeks)[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection, weekly for 6 weeks
-
Result:Showed tumor growth inhibition of 52%.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 2691109-74-5
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Puro RJ, et al. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846. [Content Brief]
[2]. Andrejeva G, et al. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J Immunol. 2021 Feb 15;206(4):712-721. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AO-176 Related Classifications
HY-P991561 Related Classifications
Powered by Bioz